Tonix Pharmaceuticals announced preclinical data on TNX-1700 and TNX-4700 immuno-oncology programs via oral and poster presentations at AACR Annual Meeting 2026.
Key takeaways
Columbia collaborators presented oral on TNX-1700 reversing aging-associated gastric inflammation and attenuating tumor progression in aged mice.
TNX-1700 showed dose-independent linear pharmacokinetics in non-human primates and transgenic mice with durable TFF2 exposure.
Company presented posters on TNX-4700 anti-BTLA antibodies with high-affinity binding, functional antagonism, and reduced Fc receptor binding.
TNX-1700 in development for gastric/colorectal cancer with PD-1 inhibitors; TNX-4700 for multiple cancers targeting BTLA/HVEM.
Presentations at AACR April 17-22, 2026; press release dated April 23, 2026.